Feedback
Settings

Settings

Goto Application

1,212 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(WFCJCYSSTXNUED-QCNRFFRDSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 122
1.WO/2026/082097POLYPEPTIDE, RNA MOLECULE AND MEDICAL USE THEREOF
WO - 23.04.2026
Int.Class C07K 14/515
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
515Angiogenic factor; Angiogenin
 Appl.No PCT/CN2025/128012 Applicant SHANGHAI REGENELEAD THERAPIES CO., LTD. Inventor ZHANG, Jiao
The present disclosure relates to a polypeptide, an RNA molecule and a medical use thereof, and specifically relates to an ANGPTL polypeptide, an RNA molecule, a polynucleotide, a vector, lipid nanoparticles, a pharmaceutical composition and a medical use thereof.
2.WO/2026/085437LYME DISEASE VACCINE AND METHOD OF USE THEREOF
WO - 23.04.2026
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
 Appl.No PCT/US2025/051464 Applicant HEALTH RESEARCH, INC. Inventor LIN, Yi-Pin
Provided is an immunogenic composition for use in raising immunity against the agent of Lyme disease. The composition is based on variants of CspZ and comprises a polypeptide of SEQ ID NO: 1, except that (a) the amino acid whose position corresponds to amino acid 188 of SEQ ID NO: 1 is any amino acid other than tyrosine; and the amino acid whose position corresponds to amino acid 192 of SEQ ID NO: 1 is any amino acid other than tyrosine; and (b) one or both of the amino acids acid whose position corresponds to amino acid 164 of SEQ ID NO: 1 may be an amino acid other than inosine and an amino acid whose position corresponds to amino acid 168 of SEQ ID NO: 1 may be an amino acid other than cysteine. Also provided is a polynucleotide encoding any of the foregoing polypeptides and a method of vaccinating against Lyme disease comprising administering the polypeptide or RNA encoding the polypeptide to a subject.
3.WO/2026/080612COMPOSITIONS AND METHODS FOR SMALL CIRCULAR RNA-BASED IMMUNOTHERAPIES
WO - 16.04.2026
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/US2025/050083 Applicant VIRGINIA COMMONWEALTH UNIVERSITY Inventor ZHU, Guizhi
Provided herein are compositions and methods for inducing an immune response using small circular ribonucleic acid (circRNA) molecules. In particular, the compositions comprise a small circRNA encoding at least one antigen or immunogenic peptide fragment, wherein the composition is self-adjuvanted and configured to elicit a T-cell–mediated immune response.
4.WO/2026/078565MESSENGER RNA ENCODING CAS9 FOR USE IN GENOME-EDITING SYSTEMS
WO - 16.04.2026
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/IB2025/060141 Applicant CRISPR THERAPEUTICS AG Inventor WANG, Albert
The present disclosure provides improved mRNAs encoding a site-directed endonuclease for use in a CRISPR/Cas system. Also provided herein are delivery systems for use of the CRISPR/Cas system in methods of in vivo and ex vivo genome editing.
5.WO/2026/080920MRNA VACCINE FOR PEANUT ALLERGY TREATMENT
WO - 16.04.2026
Int.Class A61K 39/35
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
35Allergens
 Appl.No PCT/US2025/050635 Applicant UKKO INC. Inventor OFRAN, Yanay
Disclosed herein are lipid nanoparticles comprising messenger RNA (mRNA) molecules encoding deepitoped Ara h 1 and/or de-epitoped Ara h 2, vaccines comprising the nanoparticles and methods for inducing desensitization to peanuts and/or immunomodulation of a response to peanuts in a subject allergic to peanuts.
6.2026064992β異常ヘモグロビン症を治療するためのＣＲＩＳＰＲ／ＣＡＳ関連方法および組成物
JP - 14.04.2026
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
 Appl.No 2025244943 Applicant エディタス・メディシン、インコーポレイテッド Inventor ジェニファー・リア・ゴリ
【課題】β異常ヘモグロビン症を治療するためのＣＲＩＳＰＲ／ＣＡＳ関連組成物および方法を提供する。
【解決手段】ＨＢＧ１、ＨＢＧ２、並びにＨＢＧ１及びＨＢＧ２調節領域からなる群から選択される領域内に位置する標的ドメインに相補的な標的化ドメインを含むガイドＲＮＡ（ｇＲＮＡ）分子であって、前記標的化ドメインが特定のヌクレオチド配列を含む、ｇＲＮＡ分子が提供される。
【選択図】なし
7.2026511794免疫細胞阻害分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
JP - 14.04.2026
Int.Class A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
 Appl.No 2025557021 Applicant オーエスイー・イミュノセラピューティクス Inventor ニコラ・ポワリエ
本発明は、活性化免疫細胞表面に発現される標的に特異的に結合することができる抗原結合ドメインと、前記活性化免疫細胞の活性阻害タンパク質をコードする1つ又は幾つかのmRNA分子とを含む、脂質ベースのナノ粒子、及びその使用に関する。
8.WO/2026/0758204-1BB BINDING MOLECULES, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF USE
WO - 09.04.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/046895 Applicant MODERNATX, INC. Inventor FARRINGTON, Graham
Described herein are specific single domain antibodies and binding molecules comprising such single domain antibodies that specifically bind to 4-1BB (human, or human and cynomolgus 4-1BB), as well as nucleic acids encoding the same. Also provided are nucleic acids (e.g., mRNA) encoding such single domain antibodies and binding molecules and delivery vehicles (e.g., lipid nanoparticles) encapsulating said nucleic acids. The disclosure also features methods of using such antibodies, binding molecules, nucleic acids, and delivery vehicles encapsulating said nucleic acids to treat various diseases such as cancer.
9.WO/2026/067524HERPES SIMPLEX VIRUS (HSV) VACCINE
WO - 02.04.2026
Int.Class C12N 15/38
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
34Proteins from DNA viruses
38Herpetoviridae, e.g. herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, pseudorabies virus
 Appl.No PCT/CN2025/123929 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
The present invention relates to a herpes simplex virus (HSV) vaccine. The herpes simplex virus vaccine comprises one or more of the following nucleic acids containing polynucleotides that encode HSV glycoproteins or immunogenic fragments thereof: a nucleic acid containing a polynucleotide that encodes HSV glycoprotein D or an immunogenic fragment thereof, a nucleic acid containing a polynucleotide that encodes HSV glycoprotein C or an immunogenic fragment thereof, and a nucleic acid containing a polynucleotide that encodes HSV glycoprotein E or an immunogenic fragment thereof.
10.WO/2026/067861COMPOSITION FOR TREATING HEMOGLOBINOPATHY AND USE THEREOF
WO - 02.04.2026
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/CN2025/126070 Applicant YOLTECH THERAPEUTICS CO., LTD. Inventor ZHANG, Hongling
The present disclosure provides a composition for treating hemoglobinopathy (e.g. sickle cell anemia, hemophilia, β-thalassemia, etc.). The present composition comprises a nuclease for modifying the BCL11A gene and a CRISPR-Cas system comprising a guide RNA. Also provided is a method for treatment by administering, in a subject with a hemoglobinopathy-related disease, a system that targets the BCL11A gene or a nucleic acid that encodes such a system.
# -